Rapid Medical Begins European TIGERTRIEVER Postmarket Registry
September 19, 2017—Rapid Medical, an Israel-based company focused on the development of neurovascular interventional devices, announced that the first patient was enrolled in the TIGERTRIEVER registry at the Cantonal Hospital of Lucerne, Switzerland. The registry is designed to demonstrate the benefits of the company's Tigertriever device in real-world usage.
According to the company, the European multicenter TIGERTRIEVER registry will enroll patients from centers in France and Switzerland. Tigetriever is a fully visible, controllable stentriever that is adjusted to fit the dimensions of an occluded artery causing an acute ischemic stroke. The device received CE Mark approval for use in Europe.
In Rapid Medical's announcement, Alexander von Hessling, MD, with the Division of Neuroradiology at Cantonal Hospital, commented on the first procedure in the registry, "An 87-year-old male was admitted to the hospital with an acute stroke, suffering from severe aphasia and right-sided hemiplegia. The patient was treated with the Tigertriever, which removed a large clot from his left internal carotid artery in a single attempt. The procedure went very well and took 19 minutes, including placement of a carotid stent due to a severe carotid stenosis. The patient recovered quickly and completely and was even able to sign his consent to be enrolled in this registry study 1 hour after finishing the procedure. We are happy to have enrolled the first patient and to have a leadership role in this registry."
Rapid Medical has recently announced the closing of a $9 million financing round to advance commercialization of its products.
In addition to the postmarket registry, Rapid Medical plans to initiate the prospective multicenter TIGER clinical study to support US Food and Drug Administration clearance for the Tigertriever. The TIGER study is planned to start enrolling patients in the United States, Europe, and Israel during the first half of 2018.